Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 24 · below the Ichimoku cloud · RSI 31 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $76.3K | 0.00% | 71.30K | −86% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LUCD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 19, 2026 | Matheis DennisDirector | Purchase at price 1.00 per share. | 245K | $245.27K |
| Feb 19, 2026 | Sokolov Jacque JDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | Mcgrath Dennis MChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 470K | — |
| Feb 19, 2026 | Lapidus Stanley NDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | Palumbo John RDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | Aklog LishanChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 2.17M | — |
| Feb 19, 2026 | Cox James LDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | Matheis DennisDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | White Debra JayneDirector | Stock Award(Grant) at price 0.00 per share. | 123K | — |
| Feb 19, 2026 | O'Neil ShaunPresident | Stock Award(Grant) at price 0.00 per share. | 620K | — |
| Feb 19, 2026 | Gordon Michael AdamGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 300K | — |
| Aug 19, 2025 | Matheis DennisDirector | Purchase at price 1.02 per share. | 100K | $101.84K |
| May 21, 2025 | Matheis DennisDirector | Purchase at price 1.30 - 1.32 per share. | 350K | $457.61K |
| Feb 19, 2025 | Sokolov Jacque JDirector | Stock Award(Grant) at price 0.00 per share. | 112.8K | — |
| Feb 19, 2025 | Mcgrath Dennis MChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 300K | — |
| Feb 19, 2025 | Lapidus Stanley NDirector | Stock Award(Grant) at price 0.00 per share. | 112.8K | — |
| Feb 19, 2025 | Aklog LishanChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 300K | — |
| Feb 19, 2025 | Cox James LDirector | Stock Award(Grant) at price 0.00 per share. | 112.8K | — |
| Feb 19, 2025 | Matheis DennisDirector | Stock Award(Grant) at price 0.00 per share. | 112.8K | — |
| Feb 19, 2025 | White Debra JayneDirector | Stock Award(Grant) at price 0.00 per share. | 112.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.2 | 21.0 | -20.1 | -7.0 | -3.7 | 3.9 | -18.5 | 12.3 | -23.3 | -19.3 | −44.4% | ||
| 2025 | 17.0 | 54.5 | 0.7 | -16.1 | 11.2 | -17.3 | -14.9 | 28.7 | -19.8 | 19.8 | -12.4 | 2.8 | +33.1% |
| 2024 | 0.0 | -12.8 | -34.1 | 11.2 | -1.1 | -8.0 | -2.7 | 0.3 | 1.9 | 18.9 | 3.1 | -18.0 | −41.9% |
| 2023 | -3.7 | 3.8 | 2.9 | 5.0 | 8.2 | -12.6 | 0.7 | 10.0 | -24.0 | 10.3 | 14.7 | -4.7 | +3.7% |
| 2022 | -40.0 | 16.1 | -10.2 | -37.2 | -0.5 | 7.6 | 29.6 | -25.9 | -29.5 | 25.5 | -3.1 | -26.9 | −74.7% |
| 2021 | -22.7 | -30.4 | −46.1% |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Buy / hold / sell counts